Page last updated: 2024-10-23

aspirin and Abnormalities, Congenital

aspirin has been researched along with Abnormalities, Congenital in 17 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"The purpose of this study was to determine, on the basis of published reports, whether aspirin use during the first trimester of pregnancy is associated with an increased risk of congenital malformations."8.81Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. ( Boskovic, R; Costei, A; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2002)
"The purpose of this study was to determine, on the basis of published reports, whether aspirin use during the first trimester of pregnancy is associated with an increased risk of congenital malformations."4.81Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. ( Boskovic, R; Costei, A; Koren, G; Kozer, E; Nikfar, S; Nulman, I, 2002)
"Today, pregnancy is no longer considered impossible in women with lupus."2.53Pregnancy in women with systemic lupus erythematosus (SLE). ( Moroni, G; Ponticelli, C, 2016)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19906 (35.29)18.7374
1990's3 (17.65)18.2507
2000's3 (17.65)29.6817
2010's5 (29.41)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bloor, M1
Paech, M1
Moroni, G1
Ponticelli, C1
Kristensen, DM1
Mazaud-Guittot, S1
Gaudriault, P1
Lesné, L1
Serrano, T1
Main, KM1
Jégou, B1
Luk, YS1
Man, EM1
Sy, AN1
Capone, C1
Burjonrappa, S1
Kozer, E1
Nikfar, S1
Costei, A1
Boskovic, R1
Nulman, I1
Koren, G1
HARLEY, JD1
Bonaminio, PN1
de Regnier, R1
Chang, E1
Day, N1
Manzi, S1
Ramsey-Goldman, R1
Vroom, F1
van den Berg, PB1
de Jong-van den Berg, LT1
Tunbridge, RD1
Coulam, CB1
Tiboni, GM1
Iammarrone, E1
Piccirillo, G1
Liberati, M1
Bellati, U1
Shepard, TH1
Wilson, JG1
Gavan, JA1
Nielsen, FH1
Sunde, ML1
Hoekstra, WG1
Palmer, AK1
Warkany, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Copenhagen Analgesic Study[NCT04369222]600 participants (Anticipated)Observational2020-03-01Recruiting
Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982]Phase 460 participants (Anticipated)Interventional2021-05-28Recruiting
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]11,976 participants (Actual)Interventional2016-03-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm189
Placebo Arm230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm1078
Placebo Arm1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm78
Placebo Arm101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm303
Placebo Arm353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm134
Placebo Arm152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm141
Placebo Arm166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm42
Placebo Arm30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

InterventionParticipants (Count of Participants)
Intervention Arm352
Placebo Arm325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm264
Placebo Arm309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm668
Placebo Arm754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm1506
Placebo Arm1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm214
Placebo Arm246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm26
Placebo Arm25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm54
Placebo Arm43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm9
Placebo Arm12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm23
Placebo Arm30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

InterventionParticipants (Count of Participants)
Intervention Arm290
Placebo Arm333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm8
Placebo Arm21

Reviews

5 reviews available for aspirin and Abnormalities, Congenital

ArticleYear
Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation.
    Anesthesia and analgesia, 2013, Volume: 116, Issue:5

    Topics: Abortion, Habitual; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; Aspir

2013
Pregnancy in women with systemic lupus erythematosus (SLE).
    European journal of internal medicine, 2016, Volume: 32

    Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspi

2016
Analgesic use - prevalence, biomonitoring and endocrine and reproductive effects.
    Nature reviews. Endocrinology, 2016, Volume: 12, Issue:7

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Commerce;

2016
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
    American journal of obstetrics and gynecology, 2002, Volume: 187, Issue:6

    Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities

2002
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
    American journal of obstetrics and gynecology, 2002, Volume: 187, Issue:6

    Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities

2002
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
    American journal of obstetrics and gynecology, 2002, Volume: 187, Issue:6

    Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities

2002
Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
    American journal of obstetrics and gynecology, 2002, Volume: 187, Issue:6

    Topics: Abnormalities, Drug-Induced; Aspirin; Case-Control Studies; Cohort Studies; Congenital Abnormalities

2002
The management of pregnancy in hypertensive patients.
    Postgraduate medical journal, 1994, Volume: 70, Issue:829

    Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure; Congenital Abnormalities; Female; Humans; H

1994

Other Studies

12 other studies available for aspirin and Abnormalities, Congenital

ArticleYear
Bilateral hypoplasia of the internal carotid arteries.
    Singapore medical journal, 2010, Volume: 51, Issue:9

    Topics: Angiography; Aspirin; Carotid Artery, Internal; Congenital Abnormalities; Humans; Imaging, Three-Dim

2010
Congenital spine deformities: a new screening indication for blunt cerebrovascular injuries after cervical trauma?
    Journal of pediatric surgery, 2010, Volume: 45, Issue:12

    Topics: Anticoagulants; Aspirin; Carotid Artery, Internal, Dissection; Cerebral Angiography; Cervical Atlas;

2010
GROSS CONGENITAL MALFORMATIONS IN SIBLINGS OF CHILDREN WITH GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT ERYTHROCYTES.
    Australasian annals of medicine, 1964, Volume: 13

    Topics: Abnormalities, Drug-Induced; Aspirin; Congenital Abnormalities; Erythrocytes; Glucosephosphate Dehyd

1964
Minor physical anomalies are not increased in the offspring of mothers with systemic lupus erythematosus.
    Annals of the rheumatic diseases, 2006, Volume: 65, Issue:2

    Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Congenital Abnormalities; Fe

2006
Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful?
    British journal of clinical pharmacology, 2008, Volume: 65, Issue:2

    Topics: Abortion, Spontaneous; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Congenit

2008
Hypothesis: antiphospholipid antibodies associated with congenital anomalies?
    Early pregnancy : biology and medicine : the official journal of the Society for the Investigation of Early Pregnancy, 1997, Volume: 3, Issue:2

    Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Congeni

1997
Aspirin pretreatment potentiates hyperthermia-induced teratogenesis in the mouse.
    American journal of obstetrics and gynecology, 1998, Volume: 178, Issue:2

    Topics: Animals; Aspirin; Body Temperature; Bone and Bones; Congenital Abnormalities; Female; Fever; Gestati

1998
Teratogenicity of therapeutic agents.
    Current problems in pediatrics, 1979, Volume: 10, Issue:2

    Topics: Abnormalities, Drug-Induced; Abnormalities, Radiation-Induced; Abortion, Induced; Anesthetics; Anima

1979
Congenital malformations in nonhuman primates: spontaneous and experimentally induced.
    The Anatomical record, 1967, Volume: 158, Issue:1

    Topics: Abnormalities, Drug-Induced; Aminopterin; Animals; Aspirin; Congenital Abnormalities; Female; Haplor

1967
Alleviation of the leg abnormality in zinc-deficient chicks by histamine and by various anti-arthritic agents.
    The Journal of nutrition, 1968, Volume: 94, Issue:4

    Topics: Amine Oxidase (Copper-Containing); Animals; Arthritis; Aspirin; Chickens; Congenital Abnormalities;

1968
Sporadic malformations in laboratory animals and their influence on drug testing.
    Advances in experimental medicine and biology, 1972, Volume: 27

    Topics: Abnormalities, Drug-Induced; Animals; Animals, Laboratory; Aspirin; Bone and Bones; Congenital Abnor

1972
Experimental teratology and pediatrics.
    Paediatria Universitatis Tokyo, 1970, Volume: 18

    Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Congenital Abnormalities; Female; Fetal Diseases; Mam

1970